Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06062745 · ClinicalTrials.gov registry record · Phase 1

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

A Phase 1 study of Metastatic Prostate Cancer and Advanced Prostate Cancer, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
2
Study locations

NCT06062745 is a Phase 1 study of Metastatic Prostate Cancer and Advanced Prostate Cancer that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 30 participants, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06062745, a Phase 1 study of Metastatic Prostate Cancer and Advanced Prostate Cancer, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low prostate-specific membrane antigen (PSMA) expression or has neuroendocrine features. The name of the study interventions are: * 18F-fluciclovine-PET/CT scan * Two research blood collections

Conditions Studied

Metastatic Prostate Cancer Advanced Prostate Cancer Metastatic Prostate Neuroendocrine Carcinoma

Interventions

  • DRUG 18F-fluciclovine
  • DEVICE PET/CT

Study Locations (2)

Massachusetts

  • Dana Farber Cancer Institute - Boston
  • Brigham and Womens Hospital - Boston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-02-01
Est. Completion 2028-09-01
Phase Phase 1

Sponsor

Brigham and Women's Hospital

937 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06062745

The ClinicalTrials.gov registry entry for NCT06062745 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which 18F-fluciclovine is the first listed.

NCT06062745 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06062745 about?

NCT06062745 is a clinical study titled "Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT". This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low prostate-specific membrane antigen (PSMA) expression or has neuroendocrine features....

What is the current status of trial NCT06062745?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-02-01. Estimated completion is 2028-09-01.

What conditions does trial NCT06062745 study?

This clinical trial studies the following conditions: Metastatic Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma.

What interventions are being tested in trial NCT06062745?

The interventions under investigation include: 18F-fluciclovine (DRUG), PET/CT (DEVICE).

Who is sponsoring clinical trial NCT06062745?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06062745 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Prostate Cancer

All registered trials for this condition

Advanced Prostate Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.